Evonik has signed an agreement to acquire the LACTEL business of biodegradable polymers from DURECT Corporation for US$15 million. The transaction is expected to close by Q1 2021 pending the satisfaction of certain customary closing conditions.

An offer will be extended to each of the 15 employees of DURECT located in Birmingham, Alabama, which are associated with the LACTEL business to transition to Evonik.

“The acquisition of the Lactel business will strengthen both our innovation growth field Healthcare Solutions and Evonik’s position as a globally leading CDMO for drug delivery solutions”, said Johann-Caspar Gammelin, Head of the Nutrition & Care Division of Evonik.

LACTEL brand of biodegradable, PLGA-based polymers to be integrated into Evonik’s Health Care business.

The acquisition of the LACTEL business marks a consequential step in the growth agenda of the life-science division Nutrition & Care. The LACTEL business will benefit from fast-growing markets such as advanced drug delivery, biomaterials for tissue engineering, and the 3D printing of implantable medical devices.

“It has been a pleasure working with the highly motivated and talented LACTEL team. We have confidence that Evonik will apply its resources and commitment to excellence to enable the LACTEL product line and supporting team members to thrive,” noted James E. Brown, President and Chief Executive Officer of DURECT Corporation.

With Evonik’s global reach, existing and new customers will benefit from tapping into Health Care’s twelve global laboratories staffed with formulation, application and regulatory experts to assist in bringing their products faster to the market.

“The integration of the LACTEL business into Evonik’s market-leading portfolio of functional excipients, biomaterials and integrated CDMO services will strengthen our position as a preferred development partner and solutions provider for pharmaceutical and medical device customers,” added Thomas Riermeier, Head of the Health Care business line of Evonik.